Literature DB >> 32171730

Risk Factors of Bleeding in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation.

Omar Ellouze1, Xavier Abbad2, Tiberiu Constandache2, Anis Missaoui2, Vivien Berthoud2, Theresa Daily2, Serge Aho3, Olivier Bouchot4, Belaid Bouhemad2, Pierre-Grégoire Guinot2.   

Abstract

BACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA ECMO) is increasingly being used for circulatory shock. Bleeding is a frequent complication and is associated with increased mortality. The purpose of our study was to identify factors associated with early major bleeding after VA ECMO initiation.
METHODS: We performed a retrospective observational study based on our database. In accordance with the Extracorporeal Life Support Organization definition, the population was divided in two groups: major bleeding events (group B) and no major bleeding events (group O). We collected data on all major bleeding events occurring during the first 48 hours after VA ECMO initiation.
RESULTS: Of the 243 patients analyzed, 111 patients (46%) had an early major bleeding event. Independent risk factors associated with early major bleeding events were postcardiotomy VA ECMO (odds ratio [OR] 1.98; 95% confidence interval [CI], 1.08 to 3.62; P = .02), body mass index (OR 0.91; 95% CI, 0.85 to 0.98; P = .01), hemoglobinemia (OR 0.8; 95% CI, 0.7 to 0.92; P = .002), fibrinogen (OR 0.67; 95% CI, 0.52 to 0.84; P = .001), and pH (OR 0.15; 95% CI, 0.02 to 1.04; P = .05). By using a receiver-operating characteristics curve analysis, hemoglobin level less than 9 g dL-1, fibrinogen level less than 2 g L-1, pH lower than 7.12, and body mass index below 25 kg/m2 were identified to predict early major bleeding events. Major bleeding events were independently associated with mortality (OR 2.54; CI 95%, 1.38 to 4.66; P = .01).
CONCLUSIONS: We found that postcardiotomy VA ECMO, hemoglobin levels less than 9 g dL-1, fibrinogen levels less than 2 g L-1, pH lower than 7.12, and body mass index below 25 kg/m2 were associated with a higher risk for early major bleeding events.
Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32171730     DOI: 10.1016/j.athoracsur.2020.02.012

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study.

Authors:  Alexandre Mansour; Erwan Flecher; Matthieu Schmidt; Bertrand Rozec; Isabelle Gouin-Thibault; Maxime Esvan; Claire Fougerou; Bruno Levy; Alizée Porto; James T Ross; Marylou Para; Sabrina Manganiello; Guillaume Lebreton; André Vincentelli; Nicolas Nesseler
Journal:  Intensive Care Med       Date:  2022-07-13       Impact factor: 41.787

2.  An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation.

Authors:  Yuan Teng; Shujie Yan; Gang Liu; Song Lou; Yang Zhang; Bingyang Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-29

3.  Risk factors for bleeding complications during venovenous extracorporeal membrane oxygenation as a bridge to recovery.

Authors:  Akira Kawauchi; Keibun Liu; Mitsunobu Nakamura; Hiroyuki Suzuki; Kenji Fujizuka; Minoru Nakano
Journal:  Artif Organs       Date:  2022-04-29       Impact factor: 2.663

4.  Hemostatic complications and systemic heparinization in pediatric post-cardiotomy veno-arterial extracorporeal membrane oxygenation failed to wean from cardiopulmonary bypass.

Authors:  Yu Jin; Yongli Cui; Yang Zhang; Peiyao Zhang; Liting Bai; Yixuan Li; Peng Gao; Wenting Wang; Xu Wang; Jinping Liu; Jinxiao Hu
Journal:  Transl Pediatr       Date:  2022-09

5.  Determinants of Arterial Pressure of Oxygen and Carbon Dioxide in Patients Supported by Veno-Arterial ECMO.

Authors:  Stefan Andrei; Maxime Nguyen; Vivien Berthoud; Bastian Durand; Valerian Duclos; Marie-Catherine Morgant; Olivier Bouchot; Belaid Bouhemad; Pierre-Grégoire Guinot
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.